Delving into the Latest Updates on AC-201 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TT X, TT-X

Target

JAK1 x TYK2

Action

inhibitors

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesEye Diseases

Active Indication

Plaque psoriasisSystemic Lupus ErythematosusUveitis+ [1]

Inactive Indication-

Originator Organization

Accro Bioscience (Suzhou) Co., Ltd.Startup

Active Organization

Accro Bioscience (Suzhou) Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估AC-201片在中至重度斑块状银屑病受试者中的有效性。次要目的：评估AC-201片在中至重度斑块状银屑病受试者中的安全性；评价AC-201片在中至重度斑块状银屑病受试者中的药代动力学特征；评价AC-201片在中至重度斑块状银屑病受试者中药效标志物的变化。

[Translation]

Primary objective: To evaluate the efficacy of AC-201 tablets in subjects with moderate to severe plaque psoriasis. Secondary objectives: To evaluate the safety of AC-201 tablets in subjects with moderate to severe plaque psoriasis; To evaluate the pharmacokinetic characteristics of AC-201 tablets in subjects with moderate to severe plaque psoriasis; To evaluate the changes in pharmacodynamic markers of AC-201 tablets in subjects with moderate to severe plaque psoriasis.

Start Date23 Apr 2024

Sponsor / Collaborator

Accro Bioscience (Suzhou) Co., Ltd.Startup

CTR20232985

/ CompletedPhase 1

评价AC-201片在健康受试者中的安全性、耐受性、药代动力学特征及食物影响：单中心、随机、双盲、安慰剂对照、单次/多次给药剂量递增的I期临床研究。

[Translation] Evaluation of the safety, tolerability, pharmacokinetic characteristics and food effects of AC-201 tablets in healthy subjects: a single-center, randomized, double-blind, placebo-controlled, single/multiple dose escalation phase I clinical study.

主要目的：评估健康受试者单次和多次服用AC-201片后的安全性和耐受性；次要目的：观察健康受试者单次和多次服用AC-201片后的药代动力学特征；评估食物对健康受试者口服AC-201片的药代动力学特征的影响；其他目的：探索单次给药后AC-201的生物标志物/药效标志物。

[Translation]

Primary purpose: To evaluate the safety and tolerability of AC-201 tablets after single and multiple administration in healthy subjects; Secondary purpose: To observe the pharmacokinetic characteristics of AC-201 tablets after single and multiple administration in healthy subjects; To evaluate the effect of food on the pharmacokinetic characteristics of AC-201 tablets taken orally in healthy subjects; Other purposes: To explore the biomarkers/pharmacodynamic markers of AC-201 after single administration.

Start Date16 Nov 2023

Sponsor / Collaborator

Accro Bioscience (Suzhou) Co., Ltd.Startup

100 Clinical Results associated with AC-201

Login to view more data

100 Translational Medicine associated with AC-201

Login to view more data

100 Patents (Medical) associated with AC-201

Login to view more data

5

Literatures (Medical) associated with AC-201

01 Mar 2011·The Journal of PhysiologyQ2 · MEDICINE

Presynaptic action potential waveform determines cortical synaptic latency

Q2 · MEDICINE

Article

Author: Sami Boudkkazi ; Dominique Debanne ; Laure Fronzaroli-Molinieres

Non‐technical summary Synaptic delay at cortical synapses is determined by the presynaptic release probability. We show here that the duration and amplitude of the presynaptic action potential also determine synaptic latency at neocortical and hippocampal excitatory synapses. Broadening the presynaptic spike with blockers of potassium channels increased latency by 1–2 ms. Decreasing the amplitude of the presynaptic action potential by partly blocking sodium channels reduced synaptic latency by ∼0.5 ms. These changes may contribute to stabilization of synaptic timing during repetitive stimulation. The regulation of synaptic timing by these pharmacological agents could not be attributed to modulation of axonal conduction. Rather, the effects are compatible with modifications of the kinetics of the presynaptic calcium current. We conclude that synaptic latency at cortical neurons is not constant but dynamically regulated by presynaptic action potential waveform.

01 Jun 2001·The Journal of PhysiologyQ2 · MEDICINE

Dendritic mechanisms underlying the coupling of the dendritic with the axonal action potential initiation zone of adult rat layer 5 pyramidal neurons

Q2 · MEDICINE

Article

Author: Larkum, M. E. ; Sakmann, B. ; Zhu, J. J.

Double, triple and quadruple whole‐cell voltage recordings were made simultaneously from different parts of the apical dendritic arbor and the soma of adult layer 5 (L5) pyramidal neurons. We investigated the membrane mechanisms that support the conduction of dendritic action potentials (APs) between the dendritic and axonal AP initiation zones and their influence on the subsequent AP pattern.

The duration of the current injection to the distal dendritic initiation zone controlled the degree of coupling with the axonal initiation zone and the AP pattern.

Two components of the distally evoked regenerative potential were pharmacologically distinguished: a rapidly rising peak potential that was TTX sensitive and a slowly rising plateau‐like potential that was Cd2+ and Ni2+ sensitive and present only with longer‐duration current injection.

The amplitude of the faster forward‐propagating Na+‐dependent component and the amplitude of the back‐propagating AP fell into two classes (more distinctly in the forward‐propagating case). Current injection into the dendrite altered propagation in both directions.

Somatic current injections that elicited single Na+ APs evoked bursts of Na+ APs when current was injected simultaneously into the proximal apical dendrite. The mechanism did not depend on dendritic Na+–Ca2+ APs.

A three‐compartment model of a L5 pyramidal neuron is proposed. It comprises the distal dendritic and axonal AP initiation zones and the proximal apical dendrite. Each compartment contributes to the initiation and to the pattern of AP discharge in a distinct manner. Input to the three main dendritic arbors (tuft dendrites, apical oblique dendrites and basal dendrites) has a dominant influence on only one of these compartments. Thus, the AP pattern of L5 pyramids reflects the laminar distribution of synaptic activity in a cortical column.

01 Jan 1988·Proceedings of the Western Pharmacology Society

Neural regulation of ion transport by opioids in mouse small intestine.

Article

Author: Sheldon, R J ; Burks, T F ; Malarchik, M E ; Porreca, F

100 Deals associated with AC-201

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	Phase 2	China	Accro Bioscience (Suzhou) Co., Ltd.Startup	23 Apr 2024
Systemic Lupus Erythematosus	Phase 1	China	Accro Bioscience (Suzhou) Co., Ltd.Startup	-
Uveitis	IND Approval	China	Accro Bioscience (Suzhou) Co., Ltd.Startup	26 Nov 2024
Psoriasis	IND Approval	Australia	Accro Bioscience (Suzhou) Co., Ltd.Startup	12 May 2023